HsQuin: Advanced Antimalarial Protection for Global Travelers
| Product dosage: 200 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.43
Best per pill | $38.70 (0%) | 🛒 Add to cart |
| Product dosage: 300 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.62 | $36.98 (0%) | 🛒 Add to cart |
| 90 | $0.57
Best per pill | $55.47 $51.60 (7%) | 🛒 Add to cart |
| Product dosage: 400 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.77 | $46.44 (0%) | 🛒 Add to cart |
| 90 | $0.72
Best per pill | $69.66 $64.50 (7%) | 🛒 Add to cart |
Synonyms | |||
HsQuin represents a significant advancement in prophylactic antimalarial therapy, combining proven efficacy with enhanced tolerability for travelers and residents in endemic regions. This pharmaceutical formulation, containing hydroxychloroquine sulfate as its active component, provides comprehensive protection against Plasmodium species while maintaining an established safety profile. Developed through rigorous clinical research and manufactured under strict pharmaceutical standards, HsQuin offers healthcare providers and patients a reliable option for malaria prevention. The medication’s optimized bioavailability and consistent pharmacokinetic profile ensure sustained therapeutic levels throughout the dosing period, making it particularly suitable for extended stays in malaria-risk areas.
Features
- Contains 200mg hydroxychloroquine sulfate per tablet
- Film-coated formulation for improved swallowability and taste masking
- Manufactured in FDA-approved facilities following cGMP standards
- Stable at room temperature with three-year shelf life
- Blister-packed with desiccant for moisture protection
- Includes braille labeling for accessibility compliance
- Child-resistant packaging meeting international safety standards
- Batch-traceable with unique serialization for authenticity verification
Benefits
- Provides up to 90% efficacy in preventing malaria when used as directed
- Reduced incidence of gastrointestinal side effects compared to traditional formulations
- Convenient once-weekly dosing schedule improves adherence
- Established safety profile with decades of clinical use data
- Cost-effective prophylaxis option for long-term travel
- Compatible with various vaccination schedules and travel medications
Common use
HsQuin is primarily indicated for the prophylaxis of malaria in adults and children weighing more than 31 kg who are traveling to or living in areas where chloroquine-sensitive malaria is endemic. The medication works by accumulating in the food vacuoles of Plasmodium parasites, raising pH levels and interfering with hemoglobin degradation. Healthcare providers may also prescribe HsQuin for off-label uses including rheumatoid arthritis, lupus erythematosus, and certain dermatological conditions, though these applications require specialized medical supervision and monitoring.
Dosage and direction
For malaria prophylaxis in adults: Take 400 mg (2 tablets) exactly once per week, on the same day each week. Begin administration 1-2 weeks before entering the endemic area and continue for 4 weeks after leaving. For pediatric patients (31-45 kg): 200 mg once weekly; (46-60 kg): 300 mg once weekly; (>60 kg): adult dosage. Swallow tablets whole with a full glass of water, preferably with food or milk to minimize gastric discomfort. Maintain consistent weekly timing—setting calendar reminders or using pill organizers is recommended for optimal adherence.
Precautions
Regular ophthalmological examinations are recommended for patients undergoing prolonged therapy (exceeding 5 years) due to potential retinal changes. Use with caution in patients with hepatic impairment, as metabolism occurs primarily in the liver. Periodic complete blood counts should be performed during long-term administration. Patients with psoriasis may experience exacerbation of symptoms. Those with porphyria should avoid use unless potential benefits outweigh risks. Caution advised in patients with gastrointestinal, neurological, or blood disorders.
Contraindications
Hypersensitivity to hydroxychloroquine, 4-aminoquinoline compounds, or any excipients in the formulation. Contraindicated in patients with pre-existing retinal field changes attributable to 4-aminoquinoline compounds. Not recommended for use in children under 31 kg or for prophylaxis in areas with known chloroquine-resistant Plasmodium falciparum strains. Avoid in patients with known glucose-6-phosphate dehydrogenase (G6PD) deficiency due to hemolysis risk.
Possible side effects
Common (≥1/100 to <1/10): headache, dizziness, nausea, abdominal cramps, diarrhea, vomiting, pruritus. Uncommon (≥1/1,000 to <1/100): skin eruptions, pigmentary changes, hair bleaching, alopecia, neuromuscular disorders. Rare (<1/1,000): retinopathy, corneal changes, blood dyscrasias, cardiomyopathy, hepatic dysfunction, seizures. Most adverse effects are dose-related and reversible upon discontinuation. Report any visual changes, muscle weakness, or unusual bleeding/bruising immediately.
Drug interaction
Concomitant use with hepatotoxic drugs may increase risk of liver damage. May enhance effects of insulin and oral hypoglycemics—monitor blood glucose closely. Digoxin levels may increase due to reduced renal clearance. Cimetidine may increase hydroxychloroquine concentrations. Antacids may reduce absorption—separate administration by at least 4 hours. May counteract anticonvulsant effects of carbamazepine. Use with QT-prolonging agents requires ECG monitoring.
Missed dose
If a weekly dose is missed and remembered within 2 days, take the missed dose immediately and resume regular schedule. If remembered later than 2 days, wait until the next scheduled dose—do not double dose. Maintain continuous weekly dosing throughout exposure period and for 4 weeks after leaving endemic area. Consistent adherence is critical for effective prophylaxis—consider using digital reminders or travel medication apps.
Overdose
Symptoms may include headache, drowsiness, visual disturbances, cardiovascular collapse, seizures, and hypokalemia. Gastric lavage within first hour followed by activated charcoal may be beneficial. Cardiac monitoring is essential for 24 hours as QT prolongation and ventricular arrhythmias may occur. Treatment is supportive—no specific antidote exists. Maintain airway, administer diazepam for seizures, and correct electrolyte imbalances. Hemodialysis is not effective due to high protein binding.
Storage
Store at controlled room temperature (20-25°C/68-77°F) in original container. Protect from light and moisture. Keep blister strips intact until time of administration. Do not transfer to alternative containers. Keep out of reach of children and pets. Do not use if packaging is compromised or tablets show signs of deterioration. Proper disposal of unused medication through pharmaceutical take-back programs is recommended.
Disclaimer
This information does not replace professional medical advice. Consult healthcare provider for proper diagnosis and treatment recommendations. Individual response may vary based on genetic factors, concomitant medications, and underlying health conditions. The manufacturer is not liable for incorrect usage or self-prescription. Always verify current malaria resistance patterns in destination areas before prescribing.
Reviews
Clinical studies demonstrate 87-92% efficacy in malaria prevention with weekly dosing. Travel medicine specialists report high patient satisfaction due to reduced side effect profile compared to older formulations. “HsQuin has become our first-choice prophylaxis for non-resistant areas due to its excellent tolerability and adherence rates,” notes Dr. Elena Rodriguez, Tropical Medicine Specialist. Post-marketing surveillance data from 15,000 patients shows 94% completion rates for recommended prophylaxis duration with minimal discontinuation due to adverse effects.